


A new method for the fast detection of a key antiviral

June 9 2022



Development of novel-nanobody-based lateral-flow Immunochromatographic strip test for rapid detection of recombinant human interferon α 2b. Credit: *Journal of Pharmaceutical Analysis*

Interferons are proteins that constitute an important part of our natural defense systems. These proteins also exhibit a remarkable antiviral activity. The recombinant human interferon α 2b (rhIFN α 2b) was approved by the U.S. Food and Drug Administration in 1986. It has been

used ever since as an antiviral agent for the treatment of hepatitis B and hepatitis C. Despite its widespread applications, however, there remains an issue: the detection of rhIFN α 2b is tedious and time-consuming.

Against this backdrop, researchers from China, in a new study, recently developed a novel method for the fast and efficient detection of rhIFN α 2b. This paper was made available online on 8 July 2021 and was published in the *Journal of Pharmaceutical Analysis* on 30 April 2022.

To develop their new method, they immobilized a novel nanobody on a paper strip. The nanobody used in this method was originally derived from an Alpaca—a species of the South American camelid mammal. Subsequently, it was generated in the research laboratory using recombinant DNA technology—a technique used to subclone DNA fragments in order to obtain high quantities of synthetic proteins. This is usually achieved using bacteria or other prokaryotic cells. A nanobody is a functional fragment of a larger antibody. As the immobilized novel nanobody binds rhIFN α 2b tightly and with [high specificity](#), it was used for a rapid and fool-proof detection of rhIFN α 2b.

According to Dr. Junzhi Wang, "Owing to the advantages of nanobodies in reagent preservation, production, and cost, the lateral flow immunochromatography assay using nanobodies has a high potential to replace traditional antibody-based ligand-binding assays for a rapid identification test of recombinant protein therapeutics."

The research team characterized the binding for the I22-rhIFN α 2b interaction, i.e. binding between nanobody 122 and rhIFN α 2b, using an Octet platform. The obtained data clearly indicated a tight binding. The binding specificity was further validated using Western blotting, a technique used to detect proteins using protein-specific antibodies.

"The rhIFN α 2b products currently available in China include injections,

injection powders, gels, and pastes. The immunochromatography strips can only be used to evaluate liquids or products in powder form that can be dissolved and applied to the strips. This is because the product needs to diffuse along the strip via capillary action; gels and pastes do not satisfy this requirement," explains Dr. Wang.

Quite interestingly, the developed rhIFNa2b detection assay has a detection limit of 1 µg/mL, which is lower than the existing limits. This makes it a more sensitive lab-based technique for rapid identification of rhIFNa2b. Another big advantage is the use of nanobodies for protein detection. This is because nanobodies can be obtained in an economical manner by harvesting inexpensive bacterial cells. Moreover, large volumes of nanobodies can be obtained with relative ease using routinely used laboratory techniques.

Dr. Wang says, "The operation time of rhIFNa2b identification was shortened from two days to a few minutes with our test. It can, therefore, meet the needs for rapid detection of this family of recombinant protein products on the market and provide a good foundation for improving the efficiency of market counterfeit detection. In the future, rapid detection could be carried out in an all-round manner."

In summary, the newly developed method could pave the way for smoother, faster, and accurate detection of recombinant or artificially generated proteins, making for early diagnosis and treatment of hepatitis.

More information: Xi Qin et al, Development of novel-nanobody-based lateral-flow immunochromatographic strip test for rapid detection of recombinant human interferon α2b, *Journal of Pharmaceutical Analysis* (2021). [DOI: 10.1016/j.jpha.2021.07.003](https://doi.org/10.1016/j.jpha.2021.07.003)

Provided by Cactus Communications

Citation: A new method for the fast detection of a key antiviral (2022, June 9) retrieved 28 June 2024 from <https://phys.org/news/2022-06-method-fast-key-antiviral.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.